Catalent will support the development, manufacturing, and clinical supply of Editas Medicine’s portfolio of in vivo CRISPR medicines and engineered cell medicines.

Catalent will support the development, manufacturing, and clinical supply of Editas Medicine’s portfolio of in vivo CRISPR medicines and engineered cell medicines.

Catalent today announced that Mike Riley, Region President, Biologics, North America, will present at the upcoming Disease Prevention & Control Summit, taking place virtually on July 28 – 29, 2020.

Catalent today announced that it plans to invest $30 million (€27 million) at its facility in Limoges, France, to create a European center of excellence for clinical biologics formulation development and drug product fill-finish services.

Catalent and Humanigen today announced the expansion of their relationship, under which Catalent will provide development, manufacturing and commercialization services for lenzilumab.

Catalent Biologics will provide vial filling and packaging capacity to AstraZeneca and prepare for large-scale commercial supply of the COVID-19 vaccine candidate, AZD1222.

Catalent today announced that a number of its experts will present at the upcoming Controlled Release Society (CRS) Annual Meeting, which will take place virtually on June 29 – July 2, 2020.

Catalent Biologics will provide vial filling and packaging capacity to AstraZeneca and prepare for large-scale commercial supply of the COVID-19 vaccine candidate, AZD1222.

Catalent today announced that it has signed an agreement with Spicona, Inc. to develop a virus-like protein (VLP)-based vaccine against COVID-19 at its Madison, Wisconsin facility.